Consultant at Mayo Clinic
Hematology
Dr. Shaji K. Kumar, MD
|
|
Give Review
Shaji Kumar is an expert in the field of Hematology. He received awards:"Merit Award", "William Summerskill Award", "Travel Award for Presentation at Special Topic Conference on Hepatic Veno-occlusive Disease, Atlanta, GA", "Methods in Clinical Cancer Research Award", "Cancer Education Consortium Award", "American Association of Cancer Research Award" and "Kirpal Kaur Award for Best Resident". Shaji K. Kumar, MD is a published physician. He has 98 publications published. The most current publication "The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma." He is registered with Medicare.
Publications
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
- Treatment outcomes, healthcare resource utilization, and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myel...
- New Cancers after autotransplantations for multiple myeloma.
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple my...
- International Myeloma Working Group updated criteria for the diagnosis of multiple Myeloma.
- Bisphosphonates in multiple Myeloma: a fractured consensus.
- Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma.
- Quantification of clonal circulating plasma cells in relapsed multiple Myeloma.
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple Myeloma.
- Clinical course of light-chain smouldering multiple Myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.
- Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple Myeloma.
- Risk adapted therapy for multiple Myeloma: back to basics.
- Multiple mechanisms contribute to the synergistic anti-Myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
- Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple Myeloma: results from a phase 1 study.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Second primary malignancies with lenalidomide therapy for newly diagnosed Myeloma: a meta-analysis of individual patient data.
- Maintenance therapy in multiple Myeloma.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
- Genetic variants in DNA repair pathways are not associated with Disease progression among multiple myeloma patients.
- Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance.
- Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification.
- Long term response to lenalidomide in patients with newly diagnosed multiple Myeloma.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- The clinical significance of cereblon expression in multiple Myeloma.
- Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid Cancer.
- Treatment trade-offs in Myeloma: A survey of consecutive patients about contemporary maintenance strategies.
- Responsiveness of cytogenetically discrete human Myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression le...
- Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
- Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma.
- Childhood Obesity Increases Left-Ventricular Mass Irrespective of Blood Pressure Status.
- Impact of Primary Molecular Cytogenetic Abnormalities and Risk of Progression in Smoldering Multiple Myeloma.
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced Malignancies.
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Differences in the distribution of cytogenetic subtypes between multiple Myeloma patients with and without a family history of monoclonal gammopathy and multiple mye...
- Implications of continued response after autologous stem cell transplantation for multiple Myeloma.
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial.
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
- Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrom Macroglobulinemia.
- Outcomes of patients with POEMS Syndrome treated initially with radiation.
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Efficacy of bortezomib as first-line treatment for patients with multiple Myeloma.
- Digging deeper with allogeneic transplantation in multiple Myeloma.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Salvage Second Hematopoietic Cell Transplantation in Myeloma.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival out...
- Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway.
- Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.
- Plasma cell Leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multi...
- Immunoglobulin D amyloidosis: a distinct entity.
- Bone microstructural changes revealed by HRpQCT imaging and elevated DKK1 and MIP-1? levels in patients with monoclonal gammopathy of undetermined significance.
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple Myeloma.
- Impact of gene expression profiling-based risk stratification in patients with Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Myeloma ASH 2010 highlights.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
- Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.
- Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with Immune mo...
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple Myeloma.
- Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Functional interaction of plasmacytoid dendritic cells with multiple Myeloma cells: a therapeutic target.
- Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple Myeloma or monoclonal gammopathy of undetermined significance.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple Myeloma.
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple Myeloma: a prospective study.
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
- Induction of a Chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the...
- Autologous stem cell transplant in 716 patients with multiple Myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Prognostic value of the serum free light chain ratio in newly diagnosed Myeloma: proposed incorporation into the international staging system.
- Autologous stem cell transplantation in patients of 70 years and older with multiple Myeloma: Results from a matched pair analysis.
- Malignant primary cardiac tumors: review of a single institution experience.
- Improved survival in multiple Myeloma and the impact of novel therapies.
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple Myeloma.
- Relationship between depth of response and outcome in multiple Myeloma.
- Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
- Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
- Response to rituximab in patients with type II cryoglobulinemia.
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple Myeloma.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Merit Award
- William Summerskill Award
- Travel Award for Presentation at Special Topic Conference on Hepatic Veno-occlusive Disease, Atlanta, GA
- Methods in Clinical Cancer Research Award
- Cancer Education Consortium Award
- American Association of Cancer Research Award
- Kirpal Kaur Award for Best Resident
Education
-
Mayo School of Graduate Medical Education -
All India Institute of Medical Sciences
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1568434090 | |
| NPPES Provider LastName | KUMAR | |
| NPPES Provider FirstName | SHAJI | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 356.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568434090 |
| Last Name Of The Provider | KUMAR |
| First Name Of The Provider | SHAJI |
| View All |
Similar Doctors
|
|
Dr. Charles Erlichman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa M. Baumann Kreuziger, MD |
|
|
Dr. Robert A. Kyle, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michael E. Menefee, MD |
|
|
Dr. Kostandinos Sideras, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Svetomir N. Markovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan E. Wilcox, MD |
|
|
Dr. Jessica L. Geiger, MD |
|
|
Dr. Bruce E. Pollock, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Krishna A. Patel, MD |